Welcome to our dedicated page for Anebulo Pharmaceuticals news (Ticker: ANEB), a resource for investors and traders seeking the latest updates and insights on Anebulo Pharmaceuticals stock.
Anebulo Pharmaceuticals, Inc. develops selonabant, a competitive antagonist at the human CB1 receptor, for acute cannabis-induced toxic effects. Company updates focus on clinical and regulatory progress for oral and intravenous selonabant, including work directed at acute cannabinoid intoxication and pediatric acute cannabis-induced toxicity.
Recurring ANEB news also includes operating and financial results, NIH/NIDA-supported research activity, common stock capital actions such as tender-offer results, shareholder voting matters, governance updates, and corporate-status disclosures related to listing and Exchange Act reporting obligations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Anebulo Pharmaceuticals announced positive results from its Phase 2 clinical trial of ANEB-001, aimed at treating acute cannabinoid intoxication (ACI). The trial, involving 134 healthy subjects, showed that a 10 mg dose of ANEB-001 significantly reduced THC-induced effects, improving metrics such as 'feeling high' (p=0.0001) and alertness (p=0.0042). ANEB-001 was well tolerated with no serious adverse events reported. Anebulo plans to request an End of Phase 2A meeting with the FDA by mid-2023 to discuss the results and potential next steps for development.
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) announced on March 8, 2023, the appointment of Sandra Gardiner as acting chief financial officer, succeeding Rex Merchant. Gardiner brings over 30 years of experience, previously serving as CFO at Pulse Biosciences until December 2022. The company is also engaging Potrero Hill Advisors for operational efficiencies and flexibility in finance and accounting. Anebulo is focused on developing treatments for acute cannabinoid intoxication, with its lead candidate, ANEB-001, nearing the release of final Phase 2 study data and preparing for an FDA meeting by the end of Q2 2023.
Anebulo Pharmaceuticals (NASDAQ: ANEB) reported its financial results for the quarter ending December 31, 2022. The company's operating expenses rose significantly to $3.8 million from $1.1 million in the same quarter of 2022. A net loss of $3.8 million was recorded, equating to a loss of $(0.15) per share, compared to a loss of $(0.05) per share in the prior year. The firm completed its Phase 2 trial for ANEB-001, targeting acute cannabinoid intoxication, with preliminary results showing symptom reduction. Final Phase 2 data is anticipated by the end of March 2023, followed by an EOP2A meeting with the FDA.
Anebulo Pharmaceuticals, Inc. has completed dosing in its Phase 2 clinical trial for ANEB-001, targeting acute cannabinoid intoxication (ACI) treatment. Preliminary results indicate that a 10 mg dose of ANEB-001 effectively reduced THC's psychotropic effects, notably at doses as high as 30 mg. The trial enrolled 134 healthy subjects and employed adaptive design across two parts. Full pharmacokinetics, pharmacodynamics, and safety data are anticipated by the end of Q1 2023, with an FDA meeting planned for the first half of 2023 to discuss future trial designs.
Anebulo Pharmaceuticals (NASDAQ: ANEB) reported financial results for Q1 FY 2023 on September 30, 2022. Key highlights include a positive interim data announcement for ANEB-001 from its Phase 2 clinical trial and a successful $6.6 million private placement financing. The company's operating expenses rose to $2.6 million, leading to a net loss of $2.6 million or $(0.11) per share, compared to a net loss of $1.6 million or $(0.07) per share in Q1 FY 2022. As of September 30, Anebulo has $19.2 million in cash, supporting its ongoing clinical trials and operational activities.